Pulmonary Hypertension Articles & Analysis: Older
29 news found
Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition characterized by increased pulmonary arterial pressure, vascular remodeling, and persistent inflammation. ...
In the realm of pulmonary research, the search to understand complex lung conditions has led to the development of various animal models. Among these, a new murine model from Tsijis et al stands out for its potential to investigate flow-induced pulmonary hypertension (PH) and compensatory lung growth (CLG). This blog outlines this innovative ...
(NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of ...
Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced today a $32M equity investment, from a large medical device innovator. ...
(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
(NASDAQ: XAIR) a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
(NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and, through its affiliate Beyond Cancer, Ltd., ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors, today ...
The blood pressure in the lungs can also increase, leading to pulmonary hypertension. When ASDs require closure, the current standard of care is to implant a septal occluder with a metallic frame through a minimally invasive ...
Athenson continued, “We are now much closer to improving the lives of 1.2M patients battling severe COPD and ILD (pulmonary fibrosis) and who struggle with each breath to perform the day-to-day activities that most people take for granted. ...
Food and Drug Administration (FDA) has granted approval for an amendment to the company’s PROACTIVE-HF study, a pivotal Investigational Device Exemption (IDE) trial investigating the Cordella Pulmonary Artery (PA) Pressure Sensor1, shifting the design from a randomized control study to a single-arm study. ...
Location: Caesarea, Israel and Agoura California V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devicesfor treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced today that it has successfully closed all remaining tranches of the Series C ...
With more than 300 patients treated compassionately with ACP-01 for ischemic cardiomyopathy, dilated cardiomyopathy, vascular dementia, COPD, and pulmonary hypertension, in this one-minute segment Peter recounts how his chest pain dissipated one week after his stem cell treatment, and he recounts how he felt like his life was back to normal after six weeks. ...
” The first 13 rare diseases to be focused on, organized as “Junctions,” include: Spinal Muscular Atrophy (SMA), Idiopathic Pulmonary Fibrosis (IPF), Medullary Thyroid Carcinoma (MTC), Pulmonary Arterial Hypertension (PAH), Gastrointestinal Stromal Tumor (GIST), Duchenne Muscular Dystrophy (DMD), Alagille Syndrome ...
However, we observed that Aeson® has been able to directly intraoperatively stabilize the hemodynamic situation of the patient and has also been able to cope with the high pulmonary arterial pressures. Overall, we have been impressed by the promising performance of the device and we are looking forward to include it in our portfolio to save many lives in the ...
ByCarmat
The blood pressure in the lungs can also increase, leading to pulmonary hypertension. When ASDs require closure, the current standard of care is to implant a septal occluder with a metallic frame through a minimally invasive ...
Furthermore, we are accelerating research into other indications and are looking forward to announcing results from validation studies in pulmonary hypertension," comments Gesynta Pharma's CEO, Patric Stenberg. ...
The blood pressure in the lungs can also increase, leading to pulmonary hypertension. When ASDs require closure, the standard of care is to have an occluder implanted through a minimally invasive procedure. ...
V-Wave Ltd., a cardiovascular device company developing proprietary, minimally invasive interatrial shunt devices for treating patients with severe symptomatic heart failure (HF) and pulmonary arterial hypertension (PAH), announced the appointment of Bill Hughes as its Chief Financial Officer (CFO) today. ...
tiakis Biotech AG (formerly Proteo Biotech AG) has attained another milestone in its Pulmonary Arterial Hypertension (PAH) development program by receiving the final clinical phase 1 trial report demonstrating the very good safety profile of Tiprelestat (no severe adverse occurred). ...